vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

Reports Q1 revenue $36.84M, consensus $10M. “We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes,” said Paul Sekhri, chairman, president, and CEO of vTv Therapeutics (VTVT). “Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders.”